June 2019- Volume 15, Issue 6

In this Issue

Business & Government Policy

Targets acquired

Targets acquired

A look at a few recent M&A deals in the pharma world

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

Clarifying the finish line

Clarifying the finish line

FDA releases final guidance on how interchangeability will be determined for biosimilars

Preclinical

Epilepsy faces new foe in miRNAs

Epilepsy faces new foe in miRNAs

InteRNA and UMC Utrecht publish preclinical evidence for potential of therapeutic aimed at miR-135a

Bridging the SynGAP in autism

Bridging the SynGAP in autism

A new study finds gene repair improves memory and seizures in adult autism model

Taking it straight to the eye

Taking it straight to the eye

Vector platform delivers gene therapy to the retina

Two For One

Two For One

CytoDyn seeks to evaluate PRO 140 in breast cancer and NASH

Clinical Trials

New Spinraza data

New Spinraza data

Biogen presents data affirming longer-term safety and durability of Spinraza (nusinersen) treatment

Attacking Alzheimer's disease via amyloids

Attacking Alzheimer's disease via amyloids

Consortium studies Eisai drug candidates BAN2401 and elenbecestat

Pneumococcal vaccine seems on track for Phase 3

Pneumococcal vaccine seems on track for Phase 3

Merck shares data about increased immune response from V114 in Phase 2 trials

A sight for sore eyes

A sight for sore eyes

GenSight reports marked visual improvement in Phase 3 study of rare eye disease

Contract Services

Charles River invests in Resero Analytics

Charles River invests in Resero Analytics

Access to TurboToxicology expected to provide faster delivery of high-quality toxicology reports

Shooting for the stars

Shooting for the stars

Syneos Health takes top honor at inaugural ACRP All-Stars Challenge

Forward with vaccines

Forward with vaccines

WuXi Biologics signs on for long-term vaccine manufacturing contract

Diagnostics

ArcherDX attracts money and talent

ArcherDX attracts money and talent

Company looks to advance its Reveal ctDNA 20 kits and AMP-based target enrichment system

An anti-PD-1 antibody collaboration

An anti-PD-1 antibody collaboration

Arcus and Strata announce clinical development collaboration for AB122 and predictive biomarkers

A clearer risk assessment

A clearer risk assessment

Exagen’s PC4d biomarker shows promise in determining lupus patients at risk of thrombosis

A ‘breakthrough’ for Caris

A ‘breakthrough’ for Caris

MI Transcriptome companion diagnostic test receives FDA Breakthrough Device Designation

Commentary

Two R&D cultures: Creativity and consistency

Two R&D cultures: Creativity and consistency

There is a balance that is necessary in research and development, so let's not lose sight of keeping it overall, even if many individual people (and companies and institutions) often trend more one direction or the other

Research & Development

A gene association

A gene association

Mount Sinai researchers identify twenty novel gene associations with bipolar disorder

Setting the clocks ahead for cardiac cells

Setting the clocks ahead for cardiac cells

Researchers determine a method for accelerating the maturation of iPSCs into cardiomyocytes

Q BioMed speaks up for autism

Q BioMed speaks up for autism

Research shows major breakthrough with first biomarkers for pediatric nonverbal autism subgroup

Accelerating AI adoption

Accelerating AI adoption

Group tries to reduce obstacles to AI use in life sciences

Discovery

AI gains traction

AI gains traction

Three companies kick off the second quarter with AI-based announcements

A new roadmap

A new roadmap

Scripps publishes new study on neurons and neural conditioning

A model for heart valve disease drug discovery

A model for heart valve disease drug discovery

New physiological tool featured in published paper in Experimental Biology and Medicine

Alnylam and Regeneron join on RNAi therapeutics

Alnylam and Regeneron join on RNAi therapeutics

Companies focus on ocular and CNS, and advance select programs with targets expressed in the liver

Special Reports

Special Report on Cancer: Metabolic renaissance?

Special Report on Cancer: Metabolic renaissance?

Drilling to the core of life itself: Researchers go deep into the world of metabolomics to find new therapeutic possibilities with metabo-oncology

Feature

IO Summit Show Preview: Boston-bound for immuno-oncology

IO Summit Show Preview: Boston-bound for immuno-oncology

Come to Boston again, or for the first time, to get the insight on immuno-oncology

Editor's Focus

Editor’s focus: The gene genie is out of the bottle

Editor’s focus: The gene genie is out of the bottle

Our progress in terms of genetics and genomics research has been quick since the Human Genome Project wrapped up, and that's good, but let's also take note of some of the warning flags that might be cropping up now

Q&A

Q&A: Current affairs for CAR T

Q&A: Current affairs for CAR T

Celyad details current obstacles faced by CAR T approaches, and its own efforts to address them
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Latest Issue's Magazine Cover

Latest Issue  

• Volume 17 • Issue 10 • October 2021

October 2021

October 2021 Issue